Phase
Condition
Hypercholesterolemia
Familial Hypercholesterolemia
Treatment
SHR-1918
SHR-1918 placebo
Clinical Study ID
Ages > 12 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Diagnosis of functional HoFH by either genetic or clinical criteria as defined inthe protocol
LDL-C ≥2.6mmol/L at the screening visit
Body weight ≥40 kg
Receiving stable lipid-lowering therapy for at least 28 days before enrollment.
Exclusion
Exclusion Criteria:
Treatment with an ANGPTL3 inhibitor within 24 weeks prior before screening
Previously diagnosed type 1 diabetes or poorly controlled type 2 diabetes atscreening (HbA1c > 8.5%)
eGFR <30ml/min/1.73m2 at the screening visit
CK >5times ULN at the screening visit
Study Design
Connect with a study center
The Second Xiangya Hospital of Central South University Hospital
Changsha, Hunan 410000
ChinaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.